Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Paulina Marie Budde, Helal Ahmed, Todd Covey, Cecile Krejsa, Wayne Rothbaum, Nikolas Von Bubnoff, Cyrus Khandanpour

Blood (2023) 142 (Supplement 1): 2782.

https://doi.org/10.1182/blood-2023-174895

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter

Blood (2023) 142 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2023-174749

Published: 2023

Journal Articles

IL-21 Improves Rituximab-Mediated B Cell Depletion.

Steven D. Hughes, PhD, Rafael A. Ponce, PhD, Cecile Krejsa, PhD, Werner Frings, PhD, Stephanie Bartsch, BS, Julie P. Hill, MS, Mark C. Rogge, PhD

Blood (2005) 106 (11): 345.

https://doi.org/10.1182/blood.V106.11.345.345

Published: 2005

Journal Articles

Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model.

Steve D. Hughes, PhD, Ken Bannink, Cecile Krejsa, PhD, Mark Heipel, Becky Johnson, Rick Holly, P.V. Sivakumar, PhD, Katherine Henderson, Chris Clegg, PhD, Eric Sievers, MD, Wayne Kindsvogel, PhD, Don Foster, PhD

Blood (2004) 104 (11): 1404.

https://doi.org/10.1182/blood.V104.11.1404.1404

Published: 2004

NARROW

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

IL-21 Improves Rituximab-Mediated B Cell Depletion.

Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model.

Email alerts

ASH Publications

American Society of Hematology

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

IL-21 Improves Rituximab-Mediated B Cell Depletion.

Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only